Your browser is no longer supported. Please, upgrade your browser.
China Biologic Products Holdings, Inc.
Index- P/E30.93 EPS (ttm)3.88 Insider Own45.08% Shs Outstand38.79M Perf Week1.45%
Market Cap4.66B Forward P/E20.95 EPS next Y5.73 Insider Trans0.00% Shs Float21.30M Perf Month1.82%
Income152.30M PEG2.57 EPS next Q1.35 Inst Own51.00% Short Float3.67% Perf Quarter1.36%
Sales524.40M P/S8.88 EPS this Y9.10% Inst Trans7.78% Short Ratio4.81 Perf Half Y5.44%
Book/sh51.12 P/B2.35 EPS next Y8.24% ROA7.20% Target Price102.78 Perf Year10.59%
Cash/sh30.74 P/C3.90 EPS next 5Y12.05% ROE8.20% 52W Range99.74 - 120.05 Perf YTD1.59%
Dividend- P/FCF19.44 EPS past 5Y3.30% ROI8.10% 52W High-0.05% Beta0.42
Dividend %- Quick Ratio9.90 Sales past 5Y12.10% Gross Margin65.70% 52W Low20.30% ATR1.13
Employees2269 Current Ratio11.80 Sales Q/Q9.70% Oper. Margin37.20% RSI (14)70.91 Volatility1.21% 0.90%
OptionableYes Debt/Eq0.00 EPS Q/Q115.20% Profit Margin29.00% Rel Volume2.48 Prev Close119.99
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume162.32K Price119.99
Recom3.00 SMA201.47% SMA501.43% SMA2005.02% Volume0 Change0.00%
Mar-11-19Downgrade Jefferies Hold → Underperform $67 → $62
Nov-05-18Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-06-18Downgrade Credit Suisse Outperform → Neutral
May-14-18Downgrade Jefferies Buy → Hold
May-30-17Initiated Goldman Neutral
Mar-01-16Downgrade Credit Suisse Outperform → Neutral
Oct-08-15Initiated Credit Suisse Outperform
Jul-09-15Initiated BofA/Merrill Buy $135
Jul-08-14Reiterated Aegis Capital Buy $50 → $55
Mar-14-14Initiated Oppenheimer Outperform $46
Nov-06-13Downgrade Aegis Capital Buy → Hold
Mar-14-13Reiterated Aegis Capital Buy $22 → $28
May-13-10Reiterated Brean Murray Buy $19 → $20
Mar-26-10Reiterated Brean Murray Buy $15 → $19
Apr-20-21 04:30PM  
Mar-29-21 04:30PM  
Mar-16-21 01:20PM  
Mar-01-21 08:00AM  
Jan-25-21 08:44AM  
Dec-16-20 10:36PM  
Nov-26-20 12:00AM  
Nov-24-20 04:30PM  
Nov-20-20 07:37AM  
Nov-19-20 08:09AM  
Nov-13-20 08:00AM  
Oct-09-20 12:41PM  
Aug-18-20 04:00PM  
Aug-17-20 04:30PM  
Aug-16-20 08:30AM  
Aug-10-20 08:00AM  
Jul-13-20 12:45PM  
Jun-30-20 11:18AM  
Jun-29-20 01:00AM  
Jun-26-20 12:55PM  
May-21-20 04:00PM  
May-20-20 04:45PM  
May-12-20 08:30AM  
Apr-05-20 07:44PM  
Mar-12-20 05:00PM  
Mar-10-20 10:41AM  
Mar-03-20 08:30AM  
Dec-20-19 07:02AM  
Dec-16-19 05:42PM  
Dec-12-19 09:51AM  
Dec-03-19 02:42PM  
Dec-02-19 02:57PM  
Nov-15-19 10:09AM  
Nov-13-19 04:30PM  
Nov-05-19 07:01PM  
Nov-04-19 08:30AM  
Oct-24-19 12:15PM  
Oct-17-19 08:00AM  
Oct-04-19 08:00PM  
Sep-24-19 08:00AM  
Sep-19-19 07:39AM  
Sep-18-19 11:19PM  
Aug-29-19 05:31PM  
Aug-06-19 11:23PM  
Aug-05-19 04:30PM  
Jul-26-19 04:30PM  
May-13-19 12:23PM  
May-10-19 05:45PM  
May-03-19 10:30AM  
Apr-30-19 08:00AM  
Apr-27-19 09:07AM  
Apr-26-19 10:30AM  
Apr-09-19 07:26AM  
Apr-04-19 09:19AM  
Mar-22-19 04:10AM  
Mar-20-19 07:23AM  
Mar-18-19 10:47AM  
Mar-07-19 03:21PM  
Mar-06-19 05:00PM  
Feb-25-19 08:00AM  
Feb-04-19 01:06PM  
Jan-07-19 08:00AM  
Dec-17-18 10:05AM  
Dec-14-18 08:00AM  
Dec-13-18 06:55AM  
Nov-01-18 07:20PM  
Oct-24-18 08:00AM  
Oct-04-18 12:48PM  
Sep-26-18 07:50AM  
Sep-24-18 09:44AM  
Aug-29-18 11:59AM  
Aug-28-18 05:00PM  
Aug-24-18 01:47PM  
Aug-21-18 04:05PM  
Aug-20-18 01:52PM  
Aug-13-18 08:00AM  
Aug-03-18 04:40PM  
Jul-27-18 08:00AM  
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.